Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Seaweed-derived common cold remedy aimed at crowded Asian urban hubs

Published 02/21/2017, 11:44 PM
Updated 02/21/2017, 11:48 PM
© Reuters.  Sea

Investing.com - A seaweed derived remedy that can reduce the severity of colds and flu-like symptoms in children and adults was launched in Asia on Wednesday by privately-owned Mundipharma, aiming to tap a market where high urban densities make a trip to the clinic for sneezes, coughing and upper respiratory inflammation at the top of cases seen by doctors daily.

Liew Woei Kang, a children's doctor at Gleneagles Hospital in Singapore, discussed at a press conference the high incidence of trips to clinics that rank as the top complaint by patients daily and said that frequently requests for antibiotics to treat the conditions are granted, even though the drugs won't kill the viruses that cause the symptoms.

"This is a real issue," Liew said. Ronald Eccles, a professor who runs the Common Cold Centre at the University of Cardiff in Wales, citing clinical studies, also said at the press conference that the remedy, known as carrageenan, acts like a trap for the virus to limit the spread in early stages as a natural product, thereby cutting the length of colds on a mean average of two days among adults, a factor equivalent to prescription therapies.

"Two days is exactly the same as Tamiflu and Relenza," Eccles said, referring to two therapies often used to treat severe flu symptoms.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.